VIETNARMS试验设计与统计学方面:越南丙型肝炎口服直接抗病毒药物多策略上市后试验
VIETNARMS是一项在越南开展的多臂析因随机试验,同时评估两种药物方案、三种缩短治疗策略及辅助利巴韦林,共14个随机组。研究采用贝叶斯中期监测,当某组真实治愈率低于90%的后验概率>0.95时停止招募。模拟显示该停止规则操作特性合适,中期分析可及时识别表现不佳的组。
要点
- 贝叶斯监测可早期停止治愈率低于90%的随机组,降低无效暴露。
- 方案比较非劣效界值5%,策略比较界值10%,辅助利巴韦林优效性检验。
- 真实治愈率95%时,方案和策略非劣效检验把握度均>90%。
核心结论
- 停止规则操作特性合适,中期分析可及时识别表现不佳的随机组。
- 该设计适用于评估缩短或简化丙肝治疗策略。
研究设计与样本
- VIETNARMS为析因随机多臂试验,随机分配至2种药物方案、3种缩短策略或对照、辅助利巴韦林或不加用利巴韦林,共14个随机组。
- 采用贝叶斯中期监测,当某随机组真实治愈率<90%的后验概率>0.95时停止招募。
主要发现
- 真实治愈率>90%的随机组被错误停止的概率<0.05。
- 真实治愈率<60%的组在招募约25%患者后停止概率>0.9。
- 真实治愈率80%的组在总招募完成前停止概率为0.7。
- 招募开始后7、10、13、18个月进行中期分析,停止劣效组概率良好。
- 总体真实治愈率95%时,方案和策略非劣效检验把握度>90%,利巴韦林比较检测5%绝对差异把握度>90%。
关键数值与推荐
- 非劣效界值:方案比较5%,策略比较10%;辅助利巴韦林采用优效性检验。
- 停止规则:某随机组真实治愈率<90%的后验概率>0.95时停止该组招募。
- 先验分布:真实治愈率采用Beta(4.5, 0.5)先验。
临床怎么用
- 中期分析可依据贝叶斯停止规则及时终止治愈率低的治疗组,避免无效治疗。
- 设计支持同时评估多种缩短或简化治疗策略,为扩大丙肝治疗可及性提供证据。
局限性
- 原文未报告实际试验招募完成情况或最终疗效结果。
- 停止规则操作特性基于模拟评估,实际应用需结合试验进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eliminating hepatitis C is hampered by the costs of direct-acting antiviral treatment and the need to treat hard-to-reach populations. Access could be widened by shortening or simplifying treatment, but limited research means it is unclear which approaches could achieve sufficiently high cure rates to be acceptable. We present the statistical aspects of a multi-arm trial designed to test multiple strategies simultaneously and a monitoring mechanism to detect and stop individual randomly assigned groups with unacceptably low cure rates quickly. METHODS: The VIETNARMS trial will factorially randomly assign patients to two drug regimens, three treatment-shortening strategies or control, and adjunctive ribavirin or no adjunctive ribavirin with shortening strategies (14 randomly assigned groups). We will use Bayesian monitoring at interim analyses to detect and stop recruitment into unsuccessful strategies, defined by more than 0.95 posterior probability that the true cure rate is less than 90% for the individual randomly assigned group (non-comparative). Final comparisons will be non-inferiority for regimens (margin 5%) and strategies (margin 10%) and superiority for adjunctive ribavirin. Here, we tested the operating characteristics of the stopping guideline for individual randomly assigned groups, planned interim analysis timings and explored power at the final analysis. RESULTS: A beta (4.5, 0.5) prior for the true cure rate produces less than 0.05 probability of incorrectly stopping an individual randomly assigned group with a true cure rate of more than 90%. Groups with very low cure rates (<60%) are very likely (>0.9 probability) to stop after about 25% of patients are recruited. Groups with moderately low cure rates (80%) are likely to stop (0.7 probability) before overall recruitment finishes. Interim analyses 7, 10, 13 and 18 months after recruitment commences provide good probabilities of stopping inferior individual randomly assigned groups. For an overall true cure rate of 95%, power is more than 90% to confirm non-inferiority in the regimen and strategy comparisons, regardless of the control cure rate, and to detect a 5% absolute difference in the ribavirin comparison. CONCLUSIONS: The operating characteristics of the stopping guideline are appropriate, and interim analyses can be timed to detect individual randomly assigned groups that are highly likely to have suboptimal performance at various stages. Therefore, our design is suitable for evaluating treatment-shortening or -simplifying strategies. TRIAL REGISTRATION: ISRCTN registry: ISRCTN61522291. Registered on 4 October 2019.
引用
- McCabe L, White IR, Chau NVV, et al. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials. 2020. PMID: 32423467. doi:10.1186/s13063-020-04350-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。